RecruitingNot ApplicableNCT06183684

Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System


Sponsor

Laplace Interventional, Inc

Enrollment

65 participants

Start Date

Feb 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Laplace TTVR System for people with tricuspid regurgitation. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 22 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELaplace TTVR System

Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation


Locations(10)

Tucson Medical Center

Tucson, Arizona, United States

Kaiser Permanente

San Francisco, California, United States

Piedmont Hospital

Atlanta, Georgia, United States

Mayo Clinic

Rochester, Minnesota, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Montefiore Medical Center

The Bronx, New York, United States

University Hospitals, Cleveland Medical Center

Cleveland, Ohio, United States

Oklahoma Heart Institute

Tulsa, Oklahoma, United States

Providence Heart Institute

Portland, Oregon, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06183684


Related Trials